查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1865472

可近性诊断和筛检盒市场预测至2032年：按产品、样本类型、分销管道、应用、最终用户和地区分類的全球分析

Accessible Diagnostics & Screening Kits Market Forecasts to 2032 - Global Analysis By Product, Sample Type, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球可及诊断和筛检试剂盒市场预计到 2025 年将达到 3,104.1 亿美元，到 2032 年将达到 5,459.4 亿美元，预测期内复合年增长率为 8.4%。

便捷的诊断和筛检盒是创新医疗工具，旨在提供简单、低成本且可靠的疾病早期检测方法。这些试剂盒采用简化的携带式或居家检测技术，提高了诊断的便利性和整体性，并减少了对复杂医疗基础设施的依赖。透过改善医疗服务的可近性，并支持服务不足和偏远地区的预防性筛检，这些试剂盒显着促进了及时医疗干预和更佳的人群健康管理。

人们对分散式医疗保健的兴趣日益浓厚

数位健康平台、携带式诊断工具和人工智慧分析系统的进步使得快速且准确的自我检测成为可能。这些技术帮助人们无需前往传统医疗机构即可及时获得健康评估，尤其是在医疗资源匮乏的地区。随着远端医疗和连线健诊系统的扩展，诊断试剂盒正日益融入虚拟咨询中。政府和私部门主导的居家照护推广计画正在加速已开发经济体和新兴经济体的普及。随着医疗模式向以患者为中心的模式转变，分散式诊断在提高医疗服务的可近性、可负担性和预防性医疗保健效果方面发挥关键作用。

基础设施不足

在许多中低收入地区，实验室支援有限、供应链不稳定以及冷藏保管能力不足阻碍了可靠检测结果的取得。网路连线不良和数位素养缺乏也限制了依赖即时数据共用的连网诊断平台的有效性。此外，监管分散和缺乏标准化检测通讯协定也给製造商和医疗服务提供者带来了挑战。新兴经济体在确保公平分配和检测后追踪方面面临特殊的挑战。

平台技术进步

人工智慧驱动的分析、医疗物联网 (IoMT) 和行动平台的融合正在革新就地检验和个人化诊断。云端连接设备实现了患者、临床医生和实验室之间的无缝数据共用，从而改善了临床决策和疾病早期发现。实验室晶片和生物感测器技术的进步正在降低检测时间和成本，同时提高检测准确性。各公司越来越关注互通性和支持持续健康监测的数位健康生态系统。随着数位转型加速，平台技术将成为全球医疗保健系统中扩充性、高效且易于获取的诊断解决方案的基础。

过度诊断和过度使用检测的风险

家用和自测试剂盒的快速普及带来了过度诊断和过度检测的潜在风险，这可能导致不必要的焦虑和医疗干预。在缺乏专家指导的情况下，人们可以轻易获得多种检测选择，这可能导致结果误读和不必要的治疗。缺乏明确的自测后追踪临床指引加剧了这个问题。如果管理不善，来自连网装置的数据也会增加假阳性和不准确读数。为了降低这些风险，开发人员正在优先考虑在诊断系统中整合人工智慧检验工具、数据准确性演算法和用户教育。

新冠疫情的影响：

新冠疫情大大推动了可近性诊断和筛检盒市场的发展，引发了对快速居家检测解决方案前所未有的需求激增。各国政府和卫生组织扩大了紧急使用授权范围，加速了新型诊断技术的市场化。供应链中断虽然带来了初期挑战，但最终促成了更本地化的生产和更多元化的来源。疫情过后，这些发展为可近性诊断技术的持续应用奠定了基础，使其成为建立稳健医疗卫生基础设施的基石。

预计在预测期内，自测检测套组细分市场将占据最大的市场份额。

由于消费者越来越倾向于便利、保护隐私且经济实惠的健康监测解决方案，预计在预测期内，自测检测套组细分市场将占据最大的市场份额。人工智慧驱动的结果解读、智慧型手机整合和即时数位报告等创新技术正在拓展其在各类疾病中的应用范围。各公司正致力于开发多分析物平台，以便在单一装置上检测多种疾病。旨在推广早期检测和预防保健的公共宣传宣传活动也在推动市场渗透。电子商务和药房分销管道的扩充性正在提高都市区地区的可及性。

预计在预测期内，住宅用户细分市场将实现最高的复合年增长率。

预计在预测期内，居家用户群将实现最高成长率，这主要得益于远距医疗管理和远端医疗整合的日益普及。穿戴式生物辨识感测器、应用程式连接的诊断试剂盒和人工智慧健康助理等产品的广泛应用，使得个人能够自主进行定期健康评估。消费者对健康追踪、预防性筛检和慢性病管理的日益关注，正在扩大居家检测的使用者群体。各公司正致力于开发直觉的设计和数位化平台，以简化与医疗服务提供者的资料共用和使用。疫情引发的人们转向自我护理和虚拟医疗服务的行为转变，进一步推动了这个趋势。

占比最大的地区：

由于人口快速增长、医疗保健数位化不断提高以及政府的大力支持，亚太地区预计将在预测期内占据最大的市场份额。印度、中国和日本等国家在采用携带式和人工智慧诊断技术方面处于主导地位。电子健康平台的扩展和在地化生产的努力提高了筛检盒的可及性和可负担性。区域各国政府正致力于透过公私合营和行动医疗计画来促进农村地区的医疗保健服务。不断壮大的中产阶级人口和日益增强的预防保健意识也是成长要素。

预计年复合成长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于技术创新、强有力的监管支持以及消费者意识的不断提高。美国和加拿大在人工智慧整合诊断系统、远端检测平台和互联医疗生态系统的应用方面处于主导地位。大量的研发投入，加上关键产业参与者的存在，正在加速产品创新和商业化进程。科技公司、医疗服务提供者和诊断设备製造商之间的策略联盟正在提升互通性和用户参与度。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球可近性诊断与筛检试剂盒市场（依产品划分）

  • 自测检测套组
    • 妊娠测试
    • 血糖监测
    • 新冠病毒快速检测
    • 爱滋病毒/性传染感染检测
  • 实验室筛检盒
    • 分子诊断试剂盒
    • 免疫检测盒
    • 基因筛检组合
  • 照护现场（PoC）设备
    • 血液分析仪
    • 尿液分析仪
    • 移动诊断单元
  • 其他产品

6. 全球可及性诊断与筛检试剂盒市场（依样本类型划分）

  • 血
  • 尿
  • 唾液
  • 鼻咽拭子
  • 凳子

7. 全球可及诊断与筛检试剂盒市场（按分销管道划分）

  • 直接面向消费者（DTC）
  • 电子商务平台
  • 向机构投资人销售
  • 零售药房
  • 政府采购

8. 全球可近性诊断与筛检试剂盒市场（按应用划分）

  • 感染疾病检测
  • 慢性病监测
  • 癌症筛检
  • 基因和产前检测
  • 生活方式和健康监测
  • 其他用途

9. 全球可及诊断与筛检试剂盒市场（依最终用户划分）

  • 医院和诊所
  • 诊断实验室
  • 家庭用户
  • 药局/零售连锁店
  • 非政府组织和公共卫生项目
  • 其他最终用户

10. 全球可近性诊断与筛检试剂盒市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Siemens Healthineers
  • Agappe Diagnostics
  • GE HealthCare
  • PerkinElmer
  • Roche Diagnostics
  • Agilent Technologies
  • Danaher Corporation
  • Hologic, Inc.
  • Abbott Laboratories
  • bioMerieux
  • Thermo Fisher Scientific
  • Quest Diagnostics
  • Bio-Rad Laboratories
  • Becton, Dickinson and Company（BD）
  • QuidelOrtho Corporation
Product Code: SMRC32072

According to Stratistics MRC, the Global Accessible Diagnostics & Screening Kits Market is accounted for $310.41 billion in 2025 and is expected to reach $545.94 billion by 2032 growing at a CAGR of 8.4% during the forecast period. Accessible Diagnostics & Screening Kits are innovative medical tools created to provide easy, low-cost, and reliable testing for early disease detection. They use simplified, portable, or at-home technologies to make diagnostics more convenient and inclusive, reducing dependence on advanced medical infrastructure. By improving healthcare accessibility and supporting preventive screening in underserved or remote regions, these kits contribute significantly to timely medical intervention and better population health management.

Market Dynamics:

Driver:

Increased focus on decentralized healthcare

Advancements in digital health platforms, portable diagnostic tools, and AI-based interpretation systems are facilitating rapid and accurate self-testing. These technologies empower individuals, especially in underserved areas, to access timely health assessments without visiting traditional healthcare centers. The expansion of telemedicine and connected health ecosystems is further integrating diagnostic kits into virtual consultations. Government and private initiatives promoting home-based care are accelerating adoption across both developed and emerging economies. As the healthcare model shifts toward patient-centric approaches, decentralized diagnostics are playing a key role in improving accessibility, affordability, and preventive health outcomes.

Restraint:

Lack of infrastructure

In many low- and middle-income regions, limited laboratory support, inconsistent supply chains, and insufficient cold storage capabilities hinder reliable testing outcomes. Poor internet connectivity and digital literacy also restrict the effectiveness of connected diagnostic platforms that rely on real-time data sharing. Additionally, regulatory fragmentation and lack of standardized testing protocols create challenges for manufacturers and healthcare providers. Emerging economies face particular difficulties in ensuring equitable distribution and post-test follow-up care.

Opportunity:

Advancements in platform technology

Integration of AI-driven analytics, Internet of Medical Things (IoMT), and mobile-based platforms is revolutionizing point-of-care testing and personalized diagnostics. Cloud-connected devices now enable seamless data sharing between patients, clinicians, and laboratories, improving clinical decision-making and early disease detection. The development of lab-on-a-chip and biosensor technologies is enhancing test accuracy while reducing time and cost. Companies are increasingly focusing on interoperability and digital health ecosystems that support continuous health monitoring. As digital transformation accelerates, platform technologies will serve as the foundation for scalable, efficient, and accessible diagnostic solutions across global healthcare systems.

Threat:

Risk of overdiagnosis and overuse of tests

The rapid expansion of at-home and self-administered diagnostic kits poses the potential risk of overdiagnosis and test overuse, leading to unnecessary anxiety or medical interventions. Easy access to multiple testing options without professional supervision may result in misinterpretation of results and unwarranted treatments. The lack of clear clinical guidelines for follow-up care following self-testing compounds this issue. Data from connected devices, if mismanaged, can also increase false positives or inaccurate readings. To mitigate these risks, developers are emphasizing the integration of AI validation tools, data accuracy algorithms, and user education within diagnostic systems.

Covid-19 Impact:

The Covid-19 pandemic served as a major catalyst for the Accessible Diagnostics & Screening Kits Market, driving an unprecedented surge in demand for rapid and home-based testing solutions. Governments and health agencies expanded emergency authorizations, allowing faster market entry for new diagnostic technologies. Supply chain disruptions initially posed challenges, but they ultimately led to more localized production and diversification of suppliers. Post-pandemic, these developments have paved the way for sustained adoption of accessible diagnostics as a cornerstone of resilient healthcare infrastructure.

The self-testing kits segment is expected to be the largest during the forecast period

The self-testing kits segment is expected to account for the largest market share during the forecast period, due to growing consumer preference for convenient, private, and cost-effective health monitoring solutions. Innovations such as AI-powered result interpretation, smartphone integration, and real-time digital reporting are expanding their usability across diverse disease categories. Companies are focusing on multi-analyte platforms that allow users to test for multiple conditions using a single device. Public awareness campaigns promoting early detection and preventive care are also fueling market penetration. The scalability of e-commerce and pharmacy distribution channels enhances accessibility in both urban and rural regions.

The home users segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home users segment is predicted to witness the highest growth rate, due to increasing adoption of remote health management and telemedicine integration. The availability of wearable biosensors, app-connected diagnostic kits, and AI health assistants is empowering individuals to perform regular health assessments independently. Growing consumer focus on wellness tracking, preventive screening, and chronic disease management is expanding the home testing user base. Companies are investing in intuitive designs and digital platforms that simplify usage and data sharing with healthcare providers. The pandemic-driven behavioral shift toward self-care and virtual health services continues to sustain this trend.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rapid population growth, increasing healthcare digitization, and supportive government initiatives. Countries like India, China, and Japan are leading in the adoption of portable and AI-enabled diagnostic technologies. Expanding e-health platforms and local manufacturing initiatives are improving affordability and availability of screening kits. Regional governments are promoting healthcare access in rural areas through public-private partnerships and mobile health programs. The rise of middle-class populations and growing awareness of preventive care are also key growth drivers.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, propelled by technological innovation, robust regulatory support, and increasing consumer awareness. The U.S. and Canada are leading in the deployment of AI-integrated diagnostic systems, remote testing platforms, and connected medical ecosystems. High investment in R&D, combined with the presence of key industry players, is accelerating product innovation and commercialization. Strategic collaborations among tech firms, healthcare providers, and diagnostic manufacturers are enhancing interoperability and user engagement.

Key players in the market

Some of the key players in Accessible Diagnostics & Screening Kits Market include Siemens Healthineers, Agappe Diagnostics, GE HealthCare, PerkinElmer, Roche Diagnostics, Agilent Technologies, Danaher Corporation, Hologic, Inc., Abbott Laboratories, bioMerieux, Thermo Fisher Scientific, Quest Diagnostics, Bio-Rad Laboratories, Becton, Dickinson and Company (BD), QuidelOrtho Corporation.

Key Developments:

In October 2025, GE announced it has received CE mark for its Carevance(TM) patient monitor, advancing accessible and reliable care for more customers starting in Europe. Built on GE HealthCare's clinical excellence, Carevance offers a clinically reliable and cost-effective solution with validated parameters and an intuitive, efficient workflow that can help empower care teams to stay focused on their patients.

In July 2025, Covaris, a PerkinElmer company and pioneer in sample preparation technologies, and Hamilton Company announce a strategic partnership to co-market the truXTRAC(R) FFPE SMART Solution, powered by the Hamilton(R) Sonication STAR liquid handler. This joint solution offers a fully automated, walk-away workflow that delivers unmatched performance for nucleic acid extraction from FFPE samples.

Products Covered:

  • Self-Testing Kits
  • Lab-Based Screening Kits
  • Point-of-Care (PoC) Devices
  • Other Products

Sample Types Covered:

  • Blood
  • Urine
  • Saliva
  • Nasal/Throat Swabs
  • Stool

Distribution Channels Covered:

  • Direct-to-Consumer (DTC)
  • E-commerce Platforms
  • Institutional Sales
  • Retail Pharmacies
  • Government Procurement

Applications Covered:

  • Infectious Disease Detection
  • Chronic Disease Monitoring
  • Cancer Screening
  • Genetic & Prenatal Testing
  • Lifestyle & Wellness Monitoring
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home Users
  • Pharmacies & Retail Chains
  • NGOs & Public Health Programs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Accessible Diagnostics & Screening Kits Market, By Product

  • 5.1 Introduction
  • 5.2 Self-Testing Kits
    • 5.2.1 Pregnancy Tests
    • 5.2.2 Glucose Monitoring
    • 5.2.3 COVID-19 Rapid Tests
    • 5.2.4 HIV/STI Screening
  • 5.3 Lab-Based Screening Kits
    • 5.3.1 Molecular Diagnostic Kits
    • 5.3.2 Immunoassay Kits
    • 5.3.3 Genetic Screening Panels
  • 5.4 Point-of-Care (PoC) Devices
    • 5.4.1 Blood Analyzers
    • 5.4.2 Urine Analyzers
    • 5.4.3 Mobile Diagnostic Units
  • 5.5 Other Products

6 Global Accessible Diagnostics & Screening Kits Market, By Sample Type

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Urine
  • 6.4 Saliva
  • 6.5 Nasal/Throat Swabs
  • 6.6 Stool

7 Global Accessible Diagnostics & Screening Kits Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct-to-Consumer (DTC)
  • 7.3 E-commerce Platforms
  • 7.4 Institutional Sales
  • 7.5 Retail Pharmacies
  • 7.6 Government Procurement

8 Global Accessible Diagnostics & Screening Kits Market, By Application

  • 8.1 Introduction
  • 8.2 Infectious Disease Detection
  • 8.3 Chronic Disease Monitoring
  • 8.4 Cancer Screening
  • 8.5 Genetic & Prenatal Testing
  • 8.6 Lifestyle & Wellness Monitoring
  • 8.7 Other Applications

9 Global Accessible Diagnostics & Screening Kits Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Home Users
  • 9.5 Pharmacies & Retail Chains
  • 9.6 NGOs & Public Health Programs
  • 9.7 Other End Users

10 Global Accessible Diagnostics & Screening Kits Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Siemens Healthineers
  • 12.2 Agappe Diagnostics
  • 12.3 GE HealthCare
  • 12.4 PerkinElmer
  • 12.5 Roche Diagnostics
  • 12.6 Agilent Technologies
  • 12.7 Danaher Corporation
  • 12.8 Hologic, Inc.
  • 12.9 Abbott Laboratories
  • 12.10 bioMerieux
  • 12.11 Thermo Fisher Scientific
  • 12.12 Quest Diagnostics
  • 12.13 Bio-Rad Laboratories
  • 12.14 Becton, Dickinson and Company (BD)
  • 12.15 QuidelOrtho Corporation

List of Tables

  • Table 1 Global Accessible Diagnostics & Screening Kits Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Accessible Diagnostics & Screening Kits Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Accessible Diagnostics & Screening Kits Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 4 Global Accessible Diagnostics & Screening Kits Market Outlook, By Pregnancy Tests (2024-2032) ($MN)
  • Table 5 Global Accessible Diagnostics & Screening Kits Market Outlook, By Glucose Monitoring (2024-2032) ($MN)
  • Table 6 Global Accessible Diagnostics & Screening Kits Market Outlook, By COVID-19 Rapid Tests (2024-2032) ($MN)
  • Table 7 Global Accessible Diagnostics & Screening Kits Market Outlook, By HIV/STI Screening (2024-2032) ($MN)
  • Table 8 Global Accessible Diagnostics & Screening Kits Market Outlook, By Lab-Based Screening Kits (2024-2032) ($MN)
  • Table 9 Global Accessible Diagnostics & Screening Kits Market Outlook, By Molecular Diagnostic Kits (2024-2032) ($MN)
  • Table 10 Global Accessible Diagnostics & Screening Kits Market Outlook, By Immunoassay Kits (2024-2032) ($MN)
  • Table 11 Global Accessible Diagnostics & Screening Kits Market Outlook, By Genetic Screening Panels (2024-2032) ($MN)
  • Table 12 Global Accessible Diagnostics & Screening Kits Market Outlook, By Point-of-Care (PoC) Devices (2024-2032) ($MN)
  • Table 13 Global Accessible Diagnostics & Screening Kits Market Outlook, By Blood Analyzers (2024-2032) ($MN)
  • Table 14 Global Accessible Diagnostics & Screening Kits Market Outlook, By Urine Analyzers (2024-2032) ($MN)
  • Table 15 Global Accessible Diagnostics & Screening Kits Market Outlook, By Mobile Diagnostic Units (2024-2032) ($MN)
  • Table 16 Global Accessible Diagnostics & Screening Kits Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 17 Global Accessible Diagnostics & Screening Kits Market Outlook, By Sample Type (2024-2032) ($MN)
  • Table 18 Global Accessible Diagnostics & Screening Kits Market Outlook, By Blood (2024-2032) ($MN)
  • Table 19 Global Accessible Diagnostics & Screening Kits Market Outlook, By Urine (2024-2032) ($MN)
  • Table 20 Global Accessible Diagnostics & Screening Kits Market Outlook, By Saliva (2024-2032) ($MN)
  • Table 21 Global Accessible Diagnostics & Screening Kits Market Outlook, By Nasal/Throat Swabs (2024-2032) ($MN)
  • Table 22 Global Accessible Diagnostics & Screening Kits Market Outlook, By Stool (2024-2032) ($MN)
  • Table 23 Global Accessible Diagnostics & Screening Kits Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 24 Global Accessible Diagnostics & Screening Kits Market Outlook, By Direct-to-Consumer (DTC) (2024-2032) ($MN)
  • Table 25 Global Accessible Diagnostics & Screening Kits Market Outlook, By E-commerce Platforms (2024-2032) ($MN)
  • Table 26 Global Accessible Diagnostics & Screening Kits Market Outlook, By Institutional Sales (2024-2032) ($MN)
  • Table 27 Global Accessible Diagnostics & Screening Kits Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 28 Global Accessible Diagnostics & Screening Kits Market Outlook, By Government Procurement (2024-2032) ($MN)
  • Table 29 Global Accessible Diagnostics & Screening Kits Market Outlook, By Application (2024-2032) ($MN)
  • Table 30 Global Accessible Diagnostics & Screening Kits Market Outlook, By Infectious Disease Detection (2024-2032) ($MN)
  • Table 31 Global Accessible Diagnostics & Screening Kits Market Outlook, By Chronic Disease Monitoring (2024-2032) ($MN)
  • Table 32 Global Accessible Diagnostics & Screening Kits Market Outlook, By Cancer Screening (2024-2032) ($MN)
  • Table 33 Global Accessible Diagnostics & Screening Kits Market Outlook, By Genetic & Prenatal Testing (2024-2032) ($MN)
  • Table 34 Global Accessible Diagnostics & Screening Kits Market Outlook, By Lifestyle & Wellness Monitoring (2024-2032) ($MN)
  • Table 35 Global Accessible Diagnostics & Screening Kits Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 36 Global Accessible Diagnostics & Screening Kits Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 Global Accessible Diagnostics & Screening Kits Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 38 Global Accessible Diagnostics & Screening Kits Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 39 Global Accessible Diagnostics & Screening Kits Market Outlook, By Home Users (2024-2032) ($MN)
  • Table 40 Global Accessible Diagnostics & Screening Kits Market Outlook, By Pharmacies & Retail Chains (2024-2032) ($MN)
  • Table 41 Global Accessible Diagnostics & Screening Kits Market Outlook, By NGOs & Public Health Programs (2024-2032) ($MN)
  • Table 42 Global Accessible Diagnostics & Screening Kits Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.